The Evolving Landscape of Ovarian Cancer: Innovations in Biotechnology and Artificial Intelligence- Based Screening and Treatment
- PMID: 40489020
- DOI: 10.1007/s11864-025-01331-7
The Evolving Landscape of Ovarian Cancer: Innovations in Biotechnology and Artificial Intelligence- Based Screening and Treatment
Abstract
Ovarian Cancer (OC) is a serious health problem that affects a great number of women globally. It is still one of the deadliest gynecological cancers due to restricted treatment choices and late-stage diagnosis. Worldwide, OC ranks as the seventh most commonly diagnosed kind of malignant neoplasm in women and the eighth leading cause of death in them. Because of several reasons such as genetic and economic ones, the epidemiology of OC shows disparities between races and countries. Lack of public screening program makes it difficult to diagnose this cancer earlier and as a result, most OCs are detected after they have progressed to other parts. However, advances in biotechnology and artificial intelligence (AI) are transforming both early detection and treatment strategies. Over the years, the application of AI in OC screening has shown promising results. The best way to get the drawbacks of traditional treatment methods is to combine newly developed strategies with existing treatment choices. Additionally, clinical researches are crucial to ensure the practical implementation of these advancements in healthcare settings. Utilizing state-of-the-art technologies and creative strategies will offer significant opportunity to lessen the worldwide impact of this curable cancer thereby enhancing women's quality of life in low and middle income countries (LMICs) and beyond. Hence, this review explores recent breakthroughs in ovarian cancer screening and therapy, highlighting the synergistic role of biotechnology and AI in improving patient outcomes that reshapes the ovarian cancer treatment landscape.
Keywords: Artificial intelligence; Biotechnology; Diagnosis; Ovarian cancer; Targeted therapy.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Human and Animal Rights and Informed Consent: This article does not include any studies involving human or animal subjects conducted by any of the authors. Competing interests: The authors declare no competing interests.
Similar articles
-
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280. Health Technol Assess. 2001. PMID: 11701100
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.Cochrane Database Syst Rev. 2022 Jul 12;7(7):CD008766. doi: 10.1002/14651858.CD008766.pub3. Cochrane Database Syst Rev. 2022. PMID: 35866378 Free PMC article.
-
Interventions targeted at women to encourage the uptake of cervical screening.Cochrane Database Syst Rev. 2021 Sep 6;9(9):CD002834. doi: 10.1002/14651858.CD002834.pub3. Cochrane Database Syst Rev. 2021. PMID: 34694000 Free PMC article.
-
Sexual Harassment and Prevention Training.2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Mar 29. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 36508513 Free Books & Documents.
References
-
- Pavlidis N, Rassy E, Vermorken JB, Assi T, Kattan J, Boussios S, et al. The outcome of patients with serous papillary peritoneal cancer, fallopian tube cancer, and epithelial ovarian cancer by treatment eras: 27 years data from the SEER registry. Cancer Epidemiol. 2021;75:102045. - PubMed
-
- Timmermans M, Sonke GS, Van de Vijver KK, van der Aa MA, Kruitwagen RFPM. No improvement in long-term survival for epithelial ovarian cancer patients: A population-based study between 1989 and 2014 in the Netherlands. Eur J Cancer. 2018;88:31–7. - PubMed
-
- Teng Z, Han R, Huang X, Zhou J, Yang J, Luo P et al. Increase of Incidence and Mortality of Ovarian Cancer during 2003–2012 in Jiangsu Province, China. Front Public Health [Internet]. 2016 [cited 2024 Nov 5];4. Available from: https://www.frontiersin.org/journals/public-health/articles/ https://doi.org/10.3389/fpubh.2016.00146/full
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical